

# Dysmenorrhea – Pipeline Insight, 2020

<https://marketpublishers.com/r/D9E0436AB75EN.html>

Date: November 2020

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: D9E0436AB75EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Dysmenorrhea – Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dysmenorrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Dysmenorrhea Understanding

#### Dysmenorrhea: Overview

Dysmenorrhea causes severe and frequent cramps and pain during your period. It may be either primary or secondary.

**Primary dysmenorrhea.** This occurs when you first start your period and continues throughout your life. It is usually life-long. It can cause severe and frequent menstrual cramping from severe and abnormal uterine contractions.

**Secondary dysmenorrhea.** This type is due to some physical cause. It usually starts later in life. It may be caused by another medical condition, such as pelvic inflammatory disease or endometriosis.

## Symptoms

The following are the most common symptoms of dysmenorrhea. However, each person may experience symptoms differently. Symptoms may include:

Cramping in the lower abdomen

Pain in the lower abdomen

Low back pain

Pain radiating down the legs

Nausea

Vomiting

Diarrhea

Fatigue

Weakness

Fainting

Headaches

## Diagnosis

To diagnose dysmenorrhea, the health care provider will evaluate your medical history and do a complete physical and pelvic exam. Other tests may include:

**Ultrasound.** This test uses high-frequency sound waves to create an image of the internal organs.

**Magnetic resonance imaging (MRI).** This test uses large magnets,

radiofrequencies, and a computer to make detailed images of organs and structures within the body.

Laparoscopy. This minor procedure uses a laparoscope. This is a thin tube with a lens and a light. It is inserted into an incision in the abdominal wall. Using the laparoscope to see into the pelvic and abdomen area, the doctor can often detect abnormal growths.

Hysteroscopy. This is the visual exam of the canal of the cervix and the inside of the uterus. It uses a viewing instrument (hysteroscope) inserted through the vagina.

## Treatment

Treatment to manage dysmenorrhea symptoms may include:

Prostaglandin inhibitors, such as nonsteroidal anti-inflammatory medications, or NSAIDs, such as aspirin and ibuprofen (to reduce pain)

Acetaminophen

Oral contraceptives (ovulation inhibitors)

Progesterone (hormone treatment)

Diet changes (to increase protein and decrease sugar and caffeine intake)

Vitamin supplements

Regular exercise

Heating pad across the abdomen

## Dysmenorrhea Emerging Drugs Chapters

This segment of the Dysmenorrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and

Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Dysmenorrhea Emerging Drugs

### Pelubiprofen - Daewon Pharmaceutical

Pelubiprofen is a cyclooxygenase 2 (COX-2) inhibitor approved for the treatment of osteoarthritis and back pain. It is currently in phase III stage of development for

### Pure Femme Tablets: Pure Green

Pure Femme Tablets is being developed by Pure Green for the treatment of Dysmenorrhea. It is currently in phase II stage of development.

### PNB 001: PNB Vesper Life Science

PNB 001 is being developed by PNB Vesper Life Science for the treatment of Dysmenorrhoea. PNB-001 is an isoform-selective antagonist that binds to CCK2 at 20 nM. In an isolated tissue assay, using CCK-5 as agonist the antagonizing properties were confirmed. L-365,260 was used as best CCK2 gastrin antagonist standard and PNB-001 was 10 times more potent and of much higher magnitude. It is currently in phase I stage of development.

Further product details are provided in the report.....

## Dysmenorrhea: Therapeutic Assessment

This segment of the report provides insights about the different Dysmenorrhea drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Dysmenorrhea

There are approx. 10+ key companies which are developing the therapies for Dysmenorrhea. The companies which have their Dysmenorrhea drug candidates in the

most advanced stage, i.e. phase III include Daewon Pharmaceutical and others

## Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Dysmenorrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dysmenorrhea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dysmenorrhea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dysmenorrhea drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dysmenorrhea R&D. The therapies under development are focused on novel approaches to treat/improve Dysmenorrhea.

Intellectual property of PNB-001 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World. USPTO has issued the patent on December 28, 2014.

## Dysmenorrhea Report Insights

Dysmenorrhea Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Dysmenorrhea Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Dysmenorrhea drugs?

How many Dysmenorrhea drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dysmenorrhea?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dysmenorrhea therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Dysmenorrhea and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Daewon Pharmaceutical

Pure Green

PNB Vesper Life Science Nobelpharma

Bayer

Laboratorios Andromaco

Juniper Pharmaceuticals

Vantia

PDC Biotech GmbH

## Key Products

NPC-16



BAY86-5300

Meloxicam

Lidocaine

VA111913

PDC31

Pelubiprofen

Pure Femme Tablets

PNB 001

## Contents

Introduction

Executive Summary

Dysmenorrhea: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Dysmenorrhea – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Dysmenorrhea companies' collaborations, Licensing, Acquisition -Deal Value Trends

Dysmenorrhea Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Pelubiprofen - Daewon Pharmaceutical

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

Pure Femme Tablets: Pure Green

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis  
PNB 001: PNB Vesper Life Science  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Pre-clinical and Discovery Stage Products  
Comparative Analysis  
Drug Name: Company Name  
Product Description  
Research and Development  
Product Development Activities  
Inactive Products  
Comparative Analysis  
Dysmenorrhea Key Companies  
Dysmenorrhea Key Products  
Dysmenorrhea- Unmet Needs  
Dysmenorrhea- Market Drivers and Barriers  
Dysmenorrhea- Future Perspectives and Conclusion  
Dysmenorrhea Analyst Views  
Dysmenorrhea Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Dysmenorrhea
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Dysmenorrhea
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Dysmenorrhea – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/D9E0436AB75EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D9E0436AB75EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970